Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael H Alderman

Showing results (101-110 of 119) with videos related to

Pageof 12
Sort By:
JAMA|May 22, 2003
Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysisBruce M Psaty, Thomas Lumley, Curt D Furberg, et al.
American Journal of Hypertension|October 10, 2002
Hypertension guidelines: criteria that might make them more clinically usefulMichael H Alderman, Curt D Furberg, John B Kostis, et al.
American Journal of Hypertension|November 10, 2004
Beyond hypertension toward guidelines for cardiovascular risk reductionMassimo Volpe, Michael H Alderman, Curt D Furberg, et al.
Hypertension (Dallas, Tex. : 1979)|May 9, 2018
Can We End the Salt Wars With a Randomized Clinical Trial in a Controlled Environment?Daniel W Jones, Friedrich C Luft, Paul K Whelton, et al.
Vascular Medicine (London, England)|November 28, 2012
The effects of vitamin D repletion on endothelial function and inflammation in patients with coronary artery diseaseSeth I Sokol, Vankeepuram Srinivas, Jill P Crandall, et al.
The American Journal of Cardiology|July 12, 2007
Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trialWilliam C Cushman, Richard H Grimm, Jeffrey A Cutler, et al.
Journal of the American College of Cardiology|March 19, 2004
Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE studyStevo Julius, Michael H Alderman, Gareth Beevers, et al.
The American Journal of Cardiology|November 22, 2015
Should Antihypertensive Treatment Recommendations Differ in Patients With and Without Coronary Heart Disease? (from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT])Michael H Alderman, Barry R Davis, Linda B Piller, et al.
Journal of the American Society of Hypertension : JASH|December 3, 2014
Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHATJosé-Miguel Yamal, Suzanne Oparil, Barry R Davis, et al.
Hypertension (Dallas, Tex. : 1979)|February 24, 2001
Baseline Characteristics of Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Richard H. Grimm, Karen L. Margolis, Vasilios Papademetriou, et al.
Pageof 12

Showing results (101-110 of 119) with videos related to

Sort By:
Pageof 12
JAMA|May 22, 2003
Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysisBruce M Psaty, Thomas Lumley, Curt D Furberg, et al.
American Journal of Hypertension|October 10, 2002
Hypertension guidelines: criteria that might make them more clinically usefulMichael H Alderman, Curt D Furberg, John B Kostis, et al.
American Journal of Hypertension|November 10, 2004
Beyond hypertension toward guidelines for cardiovascular risk reductionMassimo Volpe, Michael H Alderman, Curt D Furberg, et al.
Hypertension (Dallas, Tex. : 1979)|May 9, 2018
Can We End the Salt Wars With a Randomized Clinical Trial in a Controlled Environment?Daniel W Jones, Friedrich C Luft, Paul K Whelton, et al.
Vascular Medicine (London, England)|November 28, 2012
The effects of vitamin D repletion on endothelial function and inflammation in patients with coronary artery diseaseSeth I Sokol, Vankeepuram Srinivas, Jill P Crandall, et al.
The American Journal of Cardiology|July 12, 2007
Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trialWilliam C Cushman, Richard H Grimm, Jeffrey A Cutler, et al.
Journal of the American College of Cardiology|March 19, 2004
Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE studyStevo Julius, Michael H Alderman, Gareth Beevers, et al.
The American Journal of Cardiology|November 22, 2015
Should Antihypertensive Treatment Recommendations Differ in Patients With and Without Coronary Heart Disease? (from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT])Michael H Alderman, Barry R Davis, Linda B Piller, et al.
Journal of the American Society of Hypertension : JASH|December 3, 2014
Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHATJosé-Miguel Yamal, Suzanne Oparil, Barry R Davis, et al.
Hypertension (Dallas, Tex. : 1979)|February 24, 2001
Baseline Characteristics of Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Richard H. Grimm, Karen L. Margolis, Vasilios Papademetriou, et al.
Pageof 12